Bessemer Group Inc. Sells 95,578 Shares of STERIS plc $STE

Bessemer Group Inc. cut its stake in STERIS plc (NYSE:STE) by 9.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 963,448 shares of the medical equipment provider’s stock after selling 95,578 shares during the quarter. Bessemer Group Inc.’s holdings in STERIS were worth $244,253,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the stock. AustralianSuper Pty Ltd raised its holdings in STERIS by 18.4% in the 4th quarter. AustralianSuper Pty Ltd now owns 8,480 shares of the medical equipment provider’s stock worth $2,150,000 after purchasing an additional 1,316 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in STERIS by 3.5% in the 4th quarter. Thrivent Financial for Lutherans now owns 573,489 shares of the medical equipment provider’s stock worth $145,391,000 after purchasing an additional 19,655 shares in the last quarter. Pinnacle Associates Ltd. bought a new position in STERIS in the 4th quarter worth $517,000. Allworth Financial LP raised its holdings in STERIS by 45.8% in the 4th quarter. Allworth Financial LP now owns 2,089 shares of the medical equipment provider’s stock worth $530,000 after purchasing an additional 656 shares in the last quarter. Finally, Catalyst Financial Partners LLC bought a new position in STERIS in the 4th quarter worth $212,000. 94.69% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on STE shares. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Sunday, April 26th. Weiss Ratings lowered shares of STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, April 16th. Finally, KeyCorp decreased their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, STERIS has an average rating of “Moderate Buy” and an average target price of $276.75.

STERIS Stock Up 2.3%

NYSE:STE opened at $216.03 on Friday. The firm’s 50-day moving average price is $220.26 and its 200-day moving average price is $243.13. The company has a market capitalization of $21.19 billion, a PE ratio of 27.24 and a beta of 0.95. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.75. STERIS plc has a 1-year low of $195.14 and a 1-year high of $269.44.

STERIS (NYSE:STE) last released its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company earned $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. On average, equities analysts predict that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be given a $0.63 dividend. The ex-dividend date of this dividend is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. STERIS’s dividend payout ratio is currently 31.78%.

Insider Buying and Selling at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the sale, the director directly owned 705 shares of the company’s stock, valued at $167,233.05. This represents a 81.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.07% of the stock is owned by corporate insiders.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.